#genetictherapy

Antisense oligonucleotides (ASOs) represent a groundbreaking class of nucleotide-based therapeutics designed to modulate gene expression with high specificity. These synthetic strands of DNA or RNA are engineered to bind selectively to messenger RNA (mRNA), thereby influencing protein production and offering promising avenues for treating a wide range of genetic and acquired diseases. Over the past decade, the development of ASO technology has accelerated rapidly, driven by advances in molecular biology and delivery systems that enhance efficacy and reduce off-target effects. This article explores the key scientific principles, clinical applications, mechanisms of action, and the evolving landscape of antisense oligonucleotide-based therapies. Understanding the Mechanism of Action and Therapeutic Value of Antisense Oligonucleotides At the core of Antisense Oligonucleotide therapy is the ability of ASOs to bind complementary sequences of RNA. This binding can trigger various cellular processes, primarily the recruitment of RNase H enzyme that cleaves the targeted mRNA strand, leading to the reduction of harmful protein synthesis. Alternatively, some ASOs modulate splicing patterns, enhancing or silencing particular protein isoforms, which is crucial in diseases caused by aberrant splicing. The specificity of ASOs enables precise targeting of disease-causing genes without affecting other cellular functions, minimizing adverse effects commonly associated with traditional small molecule drugs. Get More Insights On :  Antisense Oligonucleotides

Major players in global Cancer Gene Therapy Market include SiBiono., Shanghai Sunway Biotech company limited, Altor Bioscience Corporation, Amgen, BioCancell, Aduro Biotech, OncoGeneX, GlobeImmune, Inc., New Link Genetics., MolMed S.p.A, ZioPharm Oncology, Gradalis, GENELUX, MultiVir.